47 results about "Mitosis" patented technology

The present invention relates to the field of therapy and drug delivery. More specifically, therapeutic methods and pharmaceutical compositions for treating disorders of blood-tissue barrier-protected organs that harbor substantial populations of postmittal neurons, such as organs derived from the neural tube, including the central nervous system and the eye. The disclosed methods and compositions involve topical administration of an effector component that targets intracellular biological targets to such organs, in combination with a saponin component that enhances the effective uptake of the effector component into cells and / or enhances the effective delivery of the effector component within cells where the biological target is present. For example, the effector component may be an oligonucleotide therapeutic that targets gene products associated with CNS and / or ocular disorders. Due to the cellular uptake stimulating and / or endosomal escape enhancing effects of the saponin component, the neuropharmaceuticals and ophthalmic compositions presented herein for topical administration to the CNS and / or eye, respectively, can be formulated with lower concentrations of the effector component and / or lower volumes, which provides safety benefits to neurons and patient comfort.

Provided are methods and compositions for treatment of angiogenic disorders using anti-VEGF agents. The anti-VEGF agents comprise VEGF binding domains and have the ability to bind vitreous. Provided are exemplary embodiments of Fc-IgG fusion proteins with VEGF binding domains with strong heparin-binding characteristics, strong inhibition of VEGF mitogenic activity, and improved pharmacokinetics, namely longer half-lives of the anti-VEGF agents and consequently less frequent dosing.

The disclosure relates to methods of treating photoreceptor disease and / or inhibiting degeneration or death of photoreceptors. The methods comprise administering to a subject in need thereof a therapeutically effective amount of an inhibitor of mitogen-activated protein kinase 11 (MAPK11), an inhibitor of casein kinase 1 (CK1), or combinations thereof. This disclosure also relates to certain inhibitors of MAPK11 or CK1 and to pharmaceutical compositions that contain such inhibitors.

This invention relates to the field of biomedicine and discloses a composition for treating non-small cell lung cancer metastasis that targets replication stress vulnerability and its application. The composition includes a dual-responsive polymer prodrug, which consists of a block copolymer backbone, a matrix metalloproteinase cleavage peptide sequence coupled to the hydrophilic end, and an active molecular group coupled to the hydrophobic end based on an asymmetric grafting structure. The active molecular group comprises a replication stress inducer and an ATR kinase inhibitor. This invention maintains the amorphous phase of the micelle core through the asymmetric grafting structure, eliminating the permeation barrier caused by spontaneous crystallization of components. This amorphous core provides a proton permeation channel, ensuring the synchronous in-situ release of multiple target drugs, thereby blocking the DNA replication fork repair pathway and inducing mitotic catastrophe, maintaining the spatiotemporal overlap of multiple drug interventions in the pathological target area, and avoiding the risk of drug resistance.

The present invention relates to an antibody-drug conjugate binding to Nectin-2 and use thereof, in which a mouse monoclonal antibody (m12G1 clone) and a chimeric anti-Nectin-2 antibody (chimeric 12G1; c12G1), which are capable of specifically targeting Nectin-2, have been prepared. The c12G1 antibody specifically bound to the C2 domain of human Nectin-2 with high affinity, but did not bind to mouse Nectin-2. Subsequently, an antibody-drug conjugate comprising a c12G1 antibody conjugated to DM1 was prepared, and as a result of examining the cytotoxic effect thereof on cancer cells in vitro and in vivo, c12G1-DM1 induced cell cycle arrest in the mitotic stage of Nectin-2-positive ovarian cancer cells, but not in Nectin-2-negative cancer cells. c12G1-DM1 induced approximately 100-fold cytotoxicity at IC50 in the range of 0.1-7.4 nM in ovarian cancer cells as compared to normal IgG-DM1, and c12G1-DM1 exhibited approximately 91% tumor growth inhibition in a mouse xenograft model transplanted with OV-90 cells. These results suggest that c12G1-DM1 can be effectively used as a potential therapeutic agent for Nectin-2-positive ovarian cancer.

A system for treating cancer is disclosed. According to an embodiment of the present invention, the system comprises: an electric field applying device for applying an electric field for tumor treatment; the delivery system is used for delivering a drug, and the drug comprises at least one of an immune checkpoint inhibitor and a chemical drug; the immune checkpoint inhibitor is selected from one of a duvaleriumab, a palbolizumab, an atelizumab, a Nasuliumab and a tereprenil monoclonal antibody; the chemical drug is selected from at least one of gemcitabine, cis-platinum, GEMOX and lenvatinib. According to the system, proliferation of the biliary tract cancer cells can be inhibited, migration of the biliary tract cancer cells can be inhibited, mitosis of the biliary tract cancer cells can be interfered, and immunogenic death of the biliary tract cancer cells can be promoted.

Cell culture media, cell culture compositions and methods for culturing cell populations (e.g., T-cell populations) are provided for expanding cell populations (e.g., T-cell populations). The media may comprise a basal growth medium, a serum or serum substitute, and one or more cytokines and / or cytokine inhibitors (e.g., IL-2, IL-4, TGF [beta], and / or anti-IFN [gamma] antibodies). The method may include contacting the population of T cells with the culture medium to expand the population of T cells. The population of T cells may comprise CD4 + and / or CD8 + primary human T cells or tumor infiltrating lymphocytes (TILs), which may be transformed to express chimeric antigen receptors (CARs) or T cell receptors (TCRs), and / or mutated by gene editing. In some embodiments, populations of expanded T cells using the media and / or methods provided herein can secrete IL-9, with increased viability, persistence, down-regulation of depletion, mitosis, activation response, early memory T cell phenotypes, or tumor control, and / or with an increased proportion of CD4 + / CD8 + T cells, relative to control populations of T cells.

The present invention relates to the field of therapy and drug delivery. More specifically, disclosed herein are therapeutic methods and pharmaceutical compositions for treating disorders of blood tissue barrier shielded organs having a large number of populations of post-mitotic neurons, such as organs derived from neural tubes, including the central nervous system and the eye. The disclosed methods and compositions involve topically applying into such organs a combination of an effector component that targets a biological target in a cell, and a saponin component that promotes effective ingestion of the effector component into the cell and / or enhances effective path steering of the effector component within the cell in which the biological target is present. For example, the effector component may be an oligonucleotide therapeutic agent targeting gene products associated with CNS and / or disorders of the eye. Due to the cellular uptake stimulating effect and / or endosomal escape enhancing effect of the saponin component, the neuropharmaceutical and ophthalmic compositions presented herein for topical administration into the CNS and / or eye, respectively, may be formulated with lower concentrations of effector components and / or in smaller volumes, this brings safety benefits to the neurons and the comfort of the patient.

Compositions of Allopregnanolone (Allo), and methods of use thereof for treating and preventing Alzheimer's Disease (AD) or dementia have been developed. In some embodiments, the amount of Allo effective to treat AD or dementia is between about 2 mg and about 10 mg, preferably 4 mg per dose. Methods for identifying subjects for treatment of AD or dementia are also provided. The methods include selecting a subject having one or more Apo E4 gene alleles. Methods of treating a human subject having AD or at risk of AD OR DEMENTIA are provided. The methods include administering a dosage of from 2 mg to 6 mg to the subject once within a 24 hour period. The dosing is repeated every seven days, or less frequently. The methods stimulate mitosis of neural progenitor cells, stimulate neurite growth and organization, protect against neural loss, or one or more of these neural processes.

This invention discloses a method for rice to withstand heat stress. RMI1 Genes and their applications. Among them... RMI1 The nucleotide sequence of the gene is shown in SEQ ID No. 1, and the amino acid sequence of the protein it encodes is shown in SEQ ID No. 2; this invention verifies RMI1 The function of the gene, RMI1 protein is located in the cell nucleus, rmi1-1 In mutants RMI1 The deletion of 33 base pairs in the gene results in the loss of 11 amino acids in the RMI1-1 protein, making... rmi1-1 High temperatures during the seedling stage cause a large number of abnormal chromosomes to adhere and fragment during the late mitotic phase of root tip cells, resulting in stunted plant growth and development. rmi1-1 High temperatures during the reproductive growth period of plants lead to a large number of chromosome fragments and adhesions in the late stage of meiosis I, resulting in sterility; high temperatures also affect the interaction between RMI1-1 protein and topoisomerase TOP3α and helicase RECQ4. rmi1-cr3 Frameshift mutations lead to abnormal embryo and endosperm development; overexpression RMI1 This invention can enhance the heat resistance of rice. RMI1 The analysis of gene function provides genetic resources for the breeding of heat-resistant rice varieties.

The invention provides an umbilical cord matrigel stem cell culture medium as well as a preparation method and application thereof, and belongs to the technical field of stem cells. Comprising the following raw materials: polyethylene glycol, cane sugar, an exosome composition, a cell factor composition, globulin, tween-80 and a PBS buffer solution. The culture medium can promote the growth of cell mitosis and mesoderm cells, the cells are not prone to deformation in in-vitro culture, the cell clone formation rate retention rate after multiple passage is high, the cells can still keep the characteristics of primary cells after being gradually differentiated, and the culture medium has wide application prospects.

The present disclosure provides methods for inducing cell cycle reentry of postmitotic cell. The present disclosure further provides cells and compositions for treating diseases, such as cardiovascular diseases, neural disorders, hearing loss, and diabetes.

The invention relates to a method of preparing a suspension of mitotically suppressed cells, comprising the steps of a) providing cells suspended in a cell culture medium, and b) suppressing the mitotic activity of the cells in the suspension, thereby obtaining mitotically suppressed cells. The step of suppressing the mitotic activity of the cells comprises the step of hypotonic treating the suspension, followed by exposing the cells to at least one freeze-thaw cycle, or vice versa or exposing the cells to two or more freeze-thaw cycles, optionally preceded by a hypotonic treatment of the suspension. In the method of the present invention the hypotonic treatment of the suspension comprises the step of adding liquid, such as water, to the suspension comprising the cells to form a hypotonic cell culture medium. The invention further relates to a method for culturing cells of interest and to the use of a hypotonic cell culture medium.

The application discloses application of a separating enzyme inhibitor in preparation of an antitumor drug, and the separating enzyme inhibitor is toxoflavin and a derivative thereof. The compound can inhibit, at a molecular level, cleavage activity of an important proteinase, namely separating enzyme, on one subunit Scc1 of a mucin; at a cellular level, the toxoflavin derivative Walrycin B can inhibit proliferation of cancer cells such as human cervical cancer (HeLa), liver cancer (HepG2), breast cancer (MCF-7) and prostate cancer (PC3), and can arrest the cell cycle of the cancer cells at a G2 / M phase; and at an allogeneic transplantation tumor animal model, the Walrycin B can significantly inhibit growth of a mouse tumor.

The invention relates to a neural tissue unit for use in implantation into the nervous system of a human or non-human mammal, wherein said neural tissue unit contains differentiated post-mitotic neuronal cells in an extracellular matrix, said unit being obtained from a cellular microcompartment comprising a hydrogel capsule surrounding the neural tissue unit, and said hydrogel capsule being at least partially removed before use of the neural tissue unit. The invention also relates to a process for preparing such a neural tissue unit.

The present application relates to the field of aquatic organism breeding technology, and particularly relates to a method for preparing rainbow trout tetraploid fry. The method provided by the present application comprises the following steps: obtaining fertilized eggs by dry fertilization of naturally matured rainbow trout parents, inducing the rainbow trout fertilized eggs to obtain tetraploid rainbow trout after 6.2-6.4 hours, and the duration of the induction is 10-18 minutes; after the tetraploid rainbow trout fry is obtained by induction, the chromosome ploidy of the fish is determined by using techniques such as chromosome karyotype analysis and flow cytometry DNA content determination, and the tetraploid rainbow trout fry is identified and screened for cultivation. The present application adopts a drug induction method, and controls the starting time and duration of the induction to inhibit the first mitosis time of the fertilized eggs, thereby improving the induction rate and survival rate of the tetraploid rainbow trout, and the induction rate of the tetraploid rainbow trout can reach 25-30%, and the survival rate of the fry can reach more than 90%.

To provide a defined culture medium for isolating stratified epithelial stem cells and stably maintaining the epigenetics of the stratified epithelial stem cells during multiple passages, and to provide clonal stratified epithelial stem cells isolated using the defined culture medium.SOLUTION: And a defined culture medium comprising each of ROCK (Rho kinase) inhibitors, mitogenic growth factors, insulin or IGF, TrkA inhibitors, and Oct4 activators, and comprising at least one of VEGF inhibitors, tyrosine kinase inhibitors, and / or FGF10 or FGF10 agonists, and optionally further comprising TGF β signaling pathway inhibitors and / or bone morphogenetic proteins (BMP) antagonists, wherein the defined culture medium supports epigenetically stable growth and proliferation of stem cells of stratified epithelial tissue origin in culture.SELECTED DRAWING: Figure 1

To provide retroviral and lentiviral vectors.SOLUTION: The invention provides a retroviral or lentiviral vector having a viral envelope comprising: (i) a mitogenic T cell activating transmembrane protein comprising a mitogenic domain and a transmembrane domain; and / or (ii) a cytokine-based T cell activating transmembrane protein comprising a cytokine domain and a transmembrane domain, wherein the mitogenic or cytokine-based T cell activating transmembrane protein is not part of the viral envelope glycoprotein. When cells such as natural killer cells are transduced with such viral vectors, they are simultaneously activated by the mitogenic T cell activating transmembrane protein and / or the cytokine-based T cell activating transmembrane protein.SELECTED DRAWING: None

The invention discloses an intestinal cancer mouse model based on Par3L gene knockout and a construction method thereof. After sgRNA is designed to knock out a promoter and a first exon of a Par3L gene of a mouse, the progeny of the obtained gene knockout mouse can spontaneously form intestinal cancer along with the increase of age, and the progeny is accompanied with a tissue infiltration phenotype. The intestinal cancer mouse model constructed by the invention can cause abnormal mitosis of intestinal cells and influence the genome stability, a good model system is provided for further research on the occurrence mechanism of intestinal cancer, and the intestinal cancer mouse model has a wide application prospect.

To provide a method for introducing a molecule into a cell with improved introduction efficiency.SOLUTION: (A) preparing cells into which molecules containing nucleic acids are to be introduced, (B) mixing the cells obtained in the step (A) with the molecules containing nucleic acids, and (C) introducing the molecules containing nucleic acids into the cells by endocytosis of the cells, wherein the step (A) is a step of adjusting cell cycle of the cells so that the cells enter G2 phase before M phase, which is mitotic phase.SELECTED DRAWING: Figure 3

The invention belongs to the technical field of plant biotechnology and crop molecular breeding, and particularly relates to an application and a method of a replication gene pair for inducing development of maize spontaneous endosperm and embryos, and the application of the replication gene pair for inducing development of maize spontaneous endosperm and embryos to ZmFIE develops a new approach for apomixis of maize. It is proved that ZmFIE2 (and the synergistic effect of ZmFIE2 and ZmFIE1) is a key factor for maintaining fertilization dependence of corn seed development, corn can be induced to generate autonomously developed endosperm and embryoid structures under the condition that exogenous genes are not introduced through mutation of the gene, and a core element is provided for fixing heterosis. An efficient germplasm innovation material is provided, the zmfie1 and zmfie2 double mutant shows more severe phenotype than a single mutant, endosperm cell differentiation in mutant grains is blocked, intracellular replication is remarkably reduced, mitotic activity is enhanced, and the strong cell cycle change is a characteristic necessary for constructing an efficient haploid induction line.

The invention discloses three tandem repeat PAV markers related to thousand seed weight of highland barley and application of the three tandem repeat PAV markers. The three PAV markers adopt an oligonucleotide probe sleeve # 8 as a probe, detection is carried out through chromosome fluorescence in situ hybridization in the mitosis metaphase of root tip cells, variations with repetitive sequence insertion fragments are respectively named as 1H-C, 3H-A and 6H-2, and types without insertion fragments are respectively named as 1H-D, 3H-B and 6H-1. Results show that the thousand seed weights of varieties containing 1H-C, 3H-A and 6H-2 are obviously higher than those of other polymorphic chromosomes respectively. The invention provides a cytological marker for thousand seed weight detection for highland barley breeding, and is beneficial to improving highland barley marker-assisted selective breeding efficiency. The influence of chromosome structure variation on the thousand seed weight of highland barley is disclosed, and important information is provided for mining environment adaptability genes and gene clusters.

Methods for predicting the therapeutic response of a cancer in a patient and / or for identifying a treatment for a patient who has been diagnosed as having or being likely to have cancer are described, comprising detecting the presence of one or more specific mitogen pathway protein variants in cancer cells of the patient, wherein the presence of the one or more mitogen pathway protein variants are indicative of response to one or more of: MAP2K1 / 2 inhibitors, BRAF inhibitors, EGFR inhibitors, PI3K inhibitors, and KRAS inhibitors Related methods and products are also described.

The invention discloses a colchicine binding site-targeted tubulin inhibitor, the structural general formula of which is selected from one of the following structures: the compound prepared by the invention is the colchicine binding site-targeted tubulin inhibitor, has obvious in-vitro anti-proliferative activity on MCF-7, MDA-MB-231, A549 and Hela tumor cells, and can obviously inhibit the invasion of MCF-7 cells. In addition, the compounds of the present invention inhibit tubulin polymerization in vitro and destroy the microtubule network of MCF-7 cells. In addition, the compound provided by the invention can also enable the mitosis cycle of cells to stop at a G2 / M phase, and induce apoptosis of tumor cells. The compound disclosed by the invention can also remarkably inhibit tumor growth in a mouse body, and has relatively small toxic and side effects.

The present application relates to the technical field of pharmacy, more particularly to a small molecule inhibitor, a synthetic method and an application. The small molecule inhibitor is a chemical structural formula as shown in formula (I) or a pharmaceutically acceptable salt comprising the chemical structural formula as shown in formula (I); the small molecule inhibitor has biological activity and can effectively inhibit cell mitosis, which is of great significance for preventing abnormal cell proliferation and the occurrence of cancer.

A machine learning framework for breast cancer histologic grading is described herein. In an example, a method involves accessing a whole slide image of a specimen. The image is processed using a first, second, third, and fourth machine learning process. A first output of the first machine learning process indicates portions of the image predicted to depict tumor cells. A second output of the second machine learning process corresponds to a mitotic count predicted score for a mitotic count depicted in the image, a third output of the third machine learning process corresponds to a nuclear pleomorphism predicted score for nuclear pleomorphism depicted in the image, and a fourth output of the fourth machine learning process corresponds to a tubule formation predicted score for tubule formation depicted in the image. A combined score of a predicted histologic grade of a disease in the image is generated based on the outputs.

The present invention relates to a method of preparing a suspension of cells with suppressed mitosis, the method comprising the steps of: a) providing cells suspended in a cell culture medium; and b) inhibiting the mitotic activity of the cells in the suspension, thereby obtaining mitotic inhibited cells. The step of inhibiting mitotic activity of cells comprises: subjecting the suspension to a hypotonic treatment followed by exposure of the cells to at least one freeze-thaw cycle, and vice versa; or exposing the cells to two or more freeze-thaw cycles, optionally performing a hypotonic treatment on the suspension prior to freeze-thaw cycles. In the methods described herein, the hypotonic treatment of the suspension comprises the step of adding a liquid, such as water, to the suspension comprising cells to form a hypotonic cell culture medium. The invention also relates to a method for culturing target cells and application of the hypotonic cell culture medium.

The disclosure includes a method for producing an expanded population of engineered γδ T cells, comprising: (a) culturing an isolated mixed cell population comprising γδ T cells with at least one T cell mitogen to produce an activated γδ T cell population; (b) depleting αβ T cells in the activated γδ T cell population to produce an enriched γδ T cell population; (c) engineering the enriched γδ T cell population to express at least one antigen recognition moiety to produce an engineered γδ T cell population, the engineering step comprising stably integrating at least one nucleic acid construct encoding said at least one antigen recognition moiety in culture conditions comprising IL-4, IL- 13, and IL-21; and (d) culturing the engineered γδ T cell population in the presence of at least one cytokine to provide the expanded population of engineered γδ T cells.

The invention relates to the technical field of biochemical sensing and fluorescence imaging, in particular to a chromazole near-infrared viscosity-sensitive probe, a preparation method thereof and application of the probe in living cell imaging. The preparation method of the probe comprises the following steps: dissolving tryptazole tetrafluoroborate and benzaldehyde or a derivative thereof in acetonitrile, stirring at room temperature to react, evaporating to remove a solvent after the reaction is finished, and separating and purifying through column chromatography to obtain the tryptazole near-infrared viscosity sensitive probe. The application of the probe in living cell nucleus imaging is to mark chromosomes in a cell mitosis process, so that chromosome migration behaviors are visualized. The probe is high in utilization rate, mild in preparation reaction condition, simple and convenient to operate, green and efficient. The cell nucleus of the living cell can be quickly dyed at low concentration, the cytoplasm, the nuclear membrane and the nucleolus of the living cell can be distinguished through the fluorescence brightness, and the mitosis process of the cell can be traced. A feasible strategy is provided for developing a near-infrared probe with a rapid cell nucleus staining function.

Provided is a method for culturing a sample of cells, which includes circulating epithelial cells, peripheral blood mononuclear cells (PBMC), or body fluid-derived cell samples (e.g. blood, ascites, pleural effusions, cerebrospinal fluids, perfusion fluids, sputum, and urine), or liquid biopsy-derived cell samples in presence of Bone Morphogentic Protein (BMP) inhibitor, a mitogenic growth factor, and a Wnt agonist, when culturing the circulating epithelial cells and relevant blood cells. Also provided is use of cell medium having a BMP inhibitor, a mitogenic growth factor, and a Wnt agonist in obtaining a cell culture of circulating epithelial cells, PBMC and body fluid-derived cells.